Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study

American Journal of Geriatric Psychiatry

Volumn 17, Issue 9, 2009, Pages 752-759

  Mohs, Richard C ^a   Shiovitz, Thomas M ^b   Tariot, Pierre N ^c   Porsteinsson, Anton P ^d   Baker, Kurt D ^a   Feldman, Peter D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b California Neuroscience Research Medical Group Inc   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Atomoxetine; Cholinesterase inhibitors; Dementia

Indexed keywords

ATOMOXETINE; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; OUTPATIENT DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCREENING; SIDE EFFECT; VOMITING;

EID: 69449085737     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181aad585     Document Type: Article

References (26)

1. Davies P: Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979; 171:319-327 (Pubitemid 10246672)
2. Whitehouse PJ, Price DL, Struble RG, et al: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215:1237-1239
3. Cummings JL: Alzheimer's disease. N Engl J Med 2004; 351:56-67
4. Zarow C, Lyness SA, Mortimer JA, et al: Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60:337-341 (Pubitemid 36314358)
5. Arnsten AF, Cai JX, Goldman-Rakic PS: The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988; 8:4287-4298
6. Arnsten AF, Goldman-Rakic PS: Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985; 230:1273-1276
7. Szot P, Leverenz JB, Peskind ER, et al: Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer's disease. Mol Brain Res 2000; 84:135-140
8. Raskind MA, Peskind ER, Holmes C, et al: Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 1999; 46:756-765 (Pubitemid 29460901)
9. Peskind ER, Tsuang DW, Bonner LT, et al: Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19:23-28 (Pubitemid 40488660)
10. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944 (Pubitemid 14076461)
11. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients by the clinician. J Psychiatr Res 1975; 12:189-198
12. Rosen W, Mohs R, Davis K: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364 (Pubitemid 14023930)
13. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32 (Pubitemid 27303107)
14. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338. Bethesda, MD, United States Department of Health, Education, and Welfare, 1976
15. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314 (Pubitemid 24382728)
16. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39 (Pubitemid 27303108)
17. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50:136-145 (Pubitemid 28106032)
18. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318:633-638 (Pubitemid 29192055)
19. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54:2269-2276 (Pubitemid 30416277)
20. Imbimbo BP: Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15:375-390 (Pubitemid 32487994)
21. Davidson M, Bierer LM, Kaminsky R, et al: Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord 1989; 3:224-227
22. Schneider LS, Olin JT, Pawluczyk S: A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993; 150:321-323
23. Bymaster FP, Katner J, Nelson DL, et al: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27:699-711 (Pubitemid 35335888)
24. Lyness SA, Zarow C, Chui HC: Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003; 24:1-23 (Pubitemid 35454140)
25. Raskind M, Kumar V, Malaty L, et al: Rivastigmine for Alzheimer's disease: improvement versus reduced worsening. Prim Care Companion J Clin Psychiatry 2000; 2:134-138
26. Thal LJ: Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20:S97-S99